46. Malignant rheumatoid arthritis Clinical trials / Disease details


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

  
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100042440
2021-01-212021-01-21Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance geneObservation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene difficult-to-treat rheumatoid arthritisThe normal group:No special treatment; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant;Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese MedicineNULLRecruiting1870BothThe normal group:15; Primary untreated group:15;Therapeutic effective group:15;Refractory (trial group):15;Refractory (control group):15;China
2ChiCTR2100042328
2021-01-192021-01-19Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant GeneEffect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene Rheumatoid arthritisThe normal group:No special treatment will be given;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow-up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent;Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)NULLRecruiting1870BothThe normal group:15;Primary untreated group:15;Therapeutic effective group:15;Observation group:15;The control group:15;China
3ChiCTR2000037675
2020-10-012020-08-30Clinical study of Shenshi Qianghuo Dihuang Decoction in the treatment of Rheumatoid arthritis from the perspective of ''7+1''Clinical study of Shenshi Qianghuo Dihuang Decoction in the treatment of Rheumatoid arthritis from the perspective of ''7+1'' Rheumatoid arthritiscontrol group:Methotrexate;experimental group:Qianghuo Dihuang Decoction + Methotrexate;Shanghai Traditional Chinese Medicine HospitalNULLRecruitingBothcontrol group:72;experimental group:72;China
4ChiCTR2000035146
2020-08-012020-08-02The effect of the IPACK block on pain after primary TKA in different levels of knee flexion deformity patients: a prospective, cohort trialThe effect of the IPACK block on pain after primary TKA in different levels of knee flexion deformity patients: a prospective, cohort trial knee osteoarthritis/ knee rheumatoid arthritisThe knee flexion deformities of different degrees were divided into different groups, and the patients without knee flexion deformity were the control group:Under the guidance of ultrasound, 20 ml 0.25% ropivacaine was injected between popliteal artery and knee joint capsule;West China Hospital, Sichuan UniversityNULLPending1880BothThe knee flexion deformities of different degrees were divided into different groups, and the patients without knee flexion deformity were the control group:80;N/AChina
5ChiCTR1900024902
2019-08-012019-08-03A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritisA randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis Rheumatoid ArthritisExperimental group:Traditional Chinese medicine (Yi-Shen Tong-Bi Tang);Positive control group:Methotrexate;The First Affiliated Hospital of Guangzhou University of Traditional Chinese MedicineNULLPending1865BothExperimental group:50;Positive control group:50;N/AChina
6ChiCTR1800019277
2018-11-012018-11-02The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patientsThe Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients Rheumatoid ArthritisControl group:MTX;Treatment group 1:Zoledronate Acid(ZA);Treatment group 2:MTX+Zoledronate Acid;Shanghai Traditional Medicine University Affiliated Guanghua HospitalNULLRecruiting1865BothControl group:22;Treatment group 1:22;Treatment group 2:22;China
7EUCTR2017-004226-15-DK
(EUCTR)
26/10/201805/01/2018 Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied. CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)
MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 20.0;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: Cannabidiol tablet 10 mg
Other descriptive name: CANNABIDIOL
Product Name: Dronabinol capsule 2.5. mg
INN or Proposed INN: DRONABINOL
King Christian 10th Hospital for RheumatologyNULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noDenmark
8ChiCTR-IPR-16009029
2016-11-012016-08-15Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid ArthritisClinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis Rheumatoid arthritisRA:the experimental group:MTX 10-15mg po qw+BiQi Capsule, 1.2g po bid;RA:the control group:MTX 10-15mg po qw+LEF, 10mg, po, bid;OA:The traditional Chinese group:BiQi Capsule, 1.2g po bid+Celecoxib capsules 0.2g po take as needed;OA:The western medicine control group:Calcitriol Soft Capsules 0.25ug, po, bid+Celecoxib capsules 0.2g po take as needed;Guangdong Provincial Hospital of Chinese MedicineNULLPending1865BothRA:the experimental group:60;RA:the control group:60;OA:The traditional Chinese group:60;OA:The western medicine control group:60;China
9ChiCTR-IPR-16008793
2016-07-152016-06-10A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritisA multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis Rheumatoid arthritisexperimental group:ZHENGQING FENGTONGNING sustained release tablets; control group:methotrexate;The combined treatment group:ZHENGQING FENGTONGNING sustained release tablets combine methotrexate;The First Affiliated Hospital of Third Military Medical UniversityNULLRecruiting1875Bothexperimental group:80; control group:80;The combined treatment group:80;China
10ChiCTR1800019290
2014-01-012018-11-03The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patientsThe Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients Rheumatoid ArthritisControl group:MTX;Treatment group 1:ZA;Treatment group 2:MTX+ZA;Xiao LianboNULLCompleted1865BothControl group:22;Treatment group 1:22;Treatment group 2:22;2 (Phase 2 study)China
11JPRN-UMIN000006702
2012/02/0111/11/2011A parallel group, randomized clinical trial on the efficacy and safety of intensive treatment strategy with MTX as the anchor-drug in patients with active early rheumatoid Arthritis rheumatoid arthritisIntensive treatment group
Period: 24 weeks
In the intensive treatment group, a patient starts treatment with MTX at 8mg/week. Dosage is increased to 0.25mg/kg/week by week 8 and is further increased to his or her maximum tolerable dosage by week 12. The maximum tolerable dosage is maintained until week 24. If a patient shows inadequate response to MTX and does not achieve SDAI(simplified disease activity index)emission or CDAI (linical disease activity index)remission by week 16, additional treatment with tacrolimus, bucillamine, sarazosulfapyridine, or biologics will be started as scheduled in the protocol.
After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72.
Conventional treatment group
Period: 24 weeks
In the control group, a patient starts treatment with MTX, tacrolimus, bucillamine, sarazosulfapyridine, or biologics by attending rheumatologists' discretion by week 24. Biologics are allowed on and after week 12. After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72.
Tokyo Medical and Dental UniversityDepartment of PharmacovigilanceComplete: follow-up continuing20years-old70years-oldMale and Female290Not applicableJapan
12NCT02779114
(ClinicalTrials.gov)
January 200916/5/2016RETRO (REduction of Therapy in RA Patients in Ongoing Remission)A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission.Rheumatoid ArthritisDrug: Control group;Other: Reduction group 1;Other: Reduction group 2University of Erlangen-Nürnberg Medical SchoolNULLRecruiting18 YearsN/ABoth318Phase 3Germany
13ChiCTR-TRC-10000850
2008-10-012010-04-26Phase III clinical trial of Iguratimodin rheumatoid arthritisPhase III clinical trial of Iguratimodin rheumatoid arthritis rheumatoid arthritis3:Experimental group: Iguratimod tablet, nimesulide dummy tablet; positive control group: taking nimesulide and Iguratimod dummy tablet; placebo group: taking Iguratimod dummy tablet and nimesulide dummy tablet. ;Anhui Medical UniversityNULLCompleted1865Both3:600;3 (Phase 3 study)China